Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardio-Obstetrics
What has been your approach to using contrast enhancement agent in the echo lab in pregnant patients if there is concern for LV thrombus or poor imaging windows for LVEF/valvular disease assessment?
Or would you recommend MRI instead?
Related Questions
When would you consider ordering additional testing such as hs-CRP, lipoprotein A levels, or CAC scoring to further risk stratify otherwise healthy pre-menopausal women with a prior history of pregnancy-related hypertension, diabetes, or premature births?
How would you counsel non-cardiologists needing to prescribe a QTc prolonging medication in a patient with an EKG showing prolonged QTc but no history of long QTc syndrome and no known cardiomyopathy?
When do you consider pacing in arrhythmogenic epilepsy?
How would you approach the timing of hemodialysis for an ESKD patient with no urgent indications who has NSTEMI with a troponin level of 10 ng/dl, has not had dialysis in 2 days, and is planned for left heart catheterization the next day?
When do you favor using cardiac CT compared to TEE for outpatient surveillance in the immediate post-Watchman period?
How do you approach inpatient DVT prophylaxis in patients already on low dose rivaroxaban 2.5 mg BID for PAD?
What are reasonable next steps in the work-up of suspected ATTR amyloidosis if the PYP scan is equivocal, in light of the potential risks of endomyocardial biopsy?
Would it be reasonable to begin considering GLP1 RAs or finerenone for patients with heart failure with recovered LVEF in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
Do you start a statin concurrently with icosapent ethyl for patients with moderate hypertriglyceridemia and high ASCVD risk, or do you prefer to start a statin alone and monitor triglyceride levels?